Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

When molds go viral: Dissecting the pathogenesis of post-viral Aspergillus pneumonias to guide immunomodulatory therapy in immunocompromised hosts

Award Number: K01AI192505
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 09/01/2025
PERIOD OF PERFORMANCE END DATE: 08/31/2030

Group Awards By:

View Award Description

When molds go viral: Dissecting the pathogenesis of post-viral Aspergillus pneumonias to guide immunomodulatory therapy in immunocompromised hosts - PROJECT SUMMARY Research objectives: Influenza- and respiratory syncytial virus-associated pulmonary aspergillosis (IAPA/RSV- APA) are deadly secondary mold infections, especially in immunocompromised patients. Promising preliminary data suggest that restoration and enhancement of epithelial resilience and attenuation of post-viral immune pa- ralysis with locally delivered (inhaled) immunomodulators may provide an innovative therapeutic avenue to im- prove the often-detrimental outcomes of post-viral mold pneumonias. This approach will be studied using nu- anced sequential infection models in mice with underlying immunosuppressive conditions, i.e., remission-induc- tion chemotherapy for acute myeloid leukemia or high-dose glucocorticosteroids. Aim 1 will provide a temporally and spatially resolved characterization of host-associated, global post-viral, and virus-specific (RSV- or influ- enza-specific) impairment of pulmonary and systemic anti-Aspergillus immune defense. Aim 2 will characterize protective immunity against IAPA and RSV-APA after nebulized immunotherapy (TLR2/6/9 agonists or GM-CSF) given at different timepoints, with or without systemic antiviral or antifungal therapy. Detailed immunologic studies and dual-RNA sequencing will unveil key components of protective immune augmentation, fungal adaptation to an altered host environment after multimodal therapy, and host biomarkers associated with favorable therapeutic outcomes. Collectively, these studies will provide comprehensive preclinical data to facilitate future clinical trans- lation of nebulized immunomodulators to protect high-risk patients from deadly secondary mold pneumonias. Candidate and career development plan: Dr. Wurster’s postgraduate training in molecular oncology combined with his postdoctoral and junior faculty experience in experimental mycology and translational immunology pro- vides him with an ideal and unique background to study fungal pathogenesis, host defense, and immunomodu- latory therapy in the context of underlying malignancy, virus-induced immune dysfunction, and opportunistic mold infection. Supported by an outstanding team of mentors and advisors with internationally recognized expertise in fungal pathogenesis and preclinical infection models (Dr. Kontoyiannis), pulmonary immunobiology and im- munotherapy (Dr. Evans), viral immunology (Dr. Chemaly), spatial transcriptomics (Dr. Wang), and dual host/fun- gal transcriptomics (Dr. Bruno), this data science-focused K01 project will provide an ideal setting for thorough training in state-of-the-art transcriptomics techniques and advanced immuno-informatics approaches for multidi- mensional data integration. These training objectives, along with dedicated leadership training, will substantially enhance Dr. Wurster’s competitiveness as an emerging independent investigator and future thought leader in experimental and translational mycology. Moreover, the strategic alignment of this K01 project with Dr. Wurster’s career goal of establishing a host-targeted precision medicine program for fungal and polymicrobial infections in immunocompromised patients, and the institutional focus on personalized care programs, will provide an optimal framework for him to succeed as a future independent group leader at MD Anderson Cancer Center.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $152,097 )
2025	2025	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Allergy and Infectious Diseases Research	000	1	8/27/2025	NEW	$152,097
														Subtotal = $152,097

Grand Total All Awards = $152,097

Top

All Categories

About

Search

Reports

Data Submission

Award Information

When molds go viral: Dissecting the pathogenesis of post-viral Aspergillus pneumonias to guide immunomodulatory therapy in immunocompromised hosts

Award Number: K01AI192505

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 09/01/2025

PERIOD OF PERFORMANCE END DATE: 08/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer